An open-label phase I study of the safety of perifosine in combination with sorafenib for patients with advanced cancers.
Phase of Trial: Phase I
Latest Information Update: 04 Jun 2015
At a glance
- Drugs Perifosine (Primary) ; Sorafenib (Primary)
- Indications Cancer; Liver cancer; Renal cancer
- Focus Adverse reactions
- Sponsors AEterna Zentaris Inc
- 10 Nov 2011 Actual end date (October 2011) added as reported by ClinicalTrials.gov.
- 10 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Jul 2011 Planned End Date changed from 1 Dec 2009 to 1 Dec 2011 according to ClinicalTrials.gov.